UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5

Benzinga Newsdesk www.benzinga.com Positive 67.1%

Neg 0% Neu 0% Pos 67.1%

UBS analyst Jonathan Yong maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $4.75 to $5.